Lancet also admitted Indian Covaxin, describes vaccine as 'highly effective'
Lancet also admitted Indian Covaxin, describes vaccine as 'highly effective'
Share:

New Delhi: There is another good news for the India-made corona vaccine 'Covaxin.' First the World Health Organization (WHO) gave the green signal and now The Lancet has described Bharat Biotech's Covaxin as "highly effective." New research by the medical journal The Lancet said on Thursday that the Covid-19 vaccine made by India Biotech is "highly effective" and is completely safe. Phase III trial data of the vaccine does not mention any safety concerns.

The Lancet said that the vaccine manufactured by Bharat Biotech against symptomatic corona patients has been found to be 77.8 per cent effective. The Lancet said in a statement that the vaccine produces a strong antibody response two weeks after both doses of the vaccine are given. The Medical Journal said that no vaccine-related deaths or any serious adverse events were reported during the trial of the vaccine involving 24,419 volunteers in the age group of 18-97 years between November 2020 and May 2021 in India.

The Lancet has released data on Phase III of the vaccine manufactured by Bharat Biotech. According to it, India's desi vaccine is not only safe and effective against Covid-19, but it is also 65.2 per cent effective against delta variants. Moreover, the vaccine is 93.4 per cent effective against severe symptomatic covid-19. The vaccine has been jointly created by Bharat Biotech and the Indian Council of Medical Research.

Covid Roundup: India registers 12,516 cases, 13K recoveries in 24 hrs

5 coaches of the train derailed suddenly and then...

Amit Shah to visit Kashi today to measure political situation

Join NewsTrack Whatsapp group
Related News